SUBSCRIBE
SUBSCRIBE

Compass Therapeutics

NEWS
Courtesy of Alexanderstock23/Shutterstock
Drug Development
Compass, Astrazeneca Move Forward in Biliary Tract Cancer Treatments
Compass and AstraZeneca have both provided updates to their clinical therapeutic programs focused on biliary tract cancers.
May 4, 2022
 · 
2 min read
 · 
Hayley Shasteen
Business
Top 20 Life Science Startups to Watch in 2019
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
November 6, 2018
 · 
12 min read
 · 
Mark Terry
IN THE PRESS
Press Releases
Compass Therapeutics to Participate in Upcoming November 2024 Investor Events
November 14, 2024
 · 
1 min read
Press Releases
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 8, 2024
 · 
7 min read
Business
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
October 4, 2024
 · 
3 min read
Press Releases
Compass Therapeutics to Participate in Upcoming Investor Events
September 3, 2024
 · 
1 min read
Press Releases
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
August 12, 2024
 · 
13 min read
Press Releases
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
August 7, 2024
 · 
1 min read
Press Releases
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
August 6, 2024
 · 
5 min read
Genetown
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
 · 
1 min read
Business
Compass Therapeutics Announces CEO Transition - May 28, 2024
May 28, 2024
 · 
2 min read
Drug Development
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the ASCO Annual Meeting 2024
May 23, 2024
 · 
6 min read
Load More
AWARDS
  • NextGen Class of 2019
JOBS